- Home
- BWLP vs IBRX Comparison
BWLP vs IBRX Comparison
Compare BWLP & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BWLP
- IBRX
- Stock Information
- Founded
- BWLP 1935
- IBRX 2014
- Country
- BWLP Singapore
- IBRX United States
- Employees
- BWLP N/A
- IBRX N/A
- Industry
- BWLP Marine Transportation
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BWLP Consumer Discretionary
- IBRX Health Care
- Exchange
- BWLP Nasdaq
- IBRX Nasdaq
- Market Cap
- BWLP 2.4B
- IBRX 2.3B
- IPO Year
- BWLP N/A
- IBRX N/A
- Fundamental
- Price
- BWLP $13.33
- IBRX $2.39
- Analyst Decision
- BWLP
- IBRX Strong Buy
- Analyst Count
- BWLP 0
- IBRX 6
- Target Price
- BWLP N/A
- IBRX $9.83
- AVG Volume (30 Days)
- BWLP 407.2K
- IBRX 9.8M
- Earning Date
- BWLP 11-27-2025
- IBRX 11-10-2025
- Dividend Yield
- BWLP 10.11%
- IBRX N/A
- EPS Growth
- BWLP N/A
- IBRX N/A
- EPS
- BWLP 1.50
- IBRX N/A
- Revenue
- BWLP $3,554,740,000.00
- IBRX $56,600,000.00
- Revenue This Year
- BWLP N/A
- IBRX $629.94
- Revenue Next Year
- BWLP $3.46
- IBRX $109.91
- P/E Ratio
- BWLP $9.39
- IBRX N/A
- Revenue Growth
- BWLP 1.27
- IBRX 4227.22
- 52 Week Low
- BWLP $7.86
- IBRX $1.83
- 52 Week High
- BWLP $16.60
- IBRX $6.08
- Technical
- Relative Strength Index (RSI)
- BWLP 51.20
- IBRX 44.87
- Support Level
- BWLP $13.26
- IBRX $2.30
- Resistance Level
- BWLP $13.70
- IBRX $2.67
- Average True Range (ATR)
- BWLP 0.31
- IBRX 0.12
- MACD
- BWLP 0.19
- IBRX -0.01
- Stochastic Oscillator
- BWLP 79.84
- IBRX 24.32
About BWLP BW LPG Limited Common Shares
BW LPG Ltd is an LPG shipping. It uses pioneering technology to power its vessels with cleaner-burning liquefied petroleum gas (LPG) and invest in R&D to take towards a zero-carbon future. The company is organized into two main segments: The shipping segment and the product services segment which buy and sell liquid petroleum gas and deliver it to customers. It generates the majority of its revenue from the shipping segment.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.